Eric Feinstein, MD
Ophthalmology · Orlando, FLNPI 1720340136
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 187 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 26.9% of the total.
Across 187 payments — averaging $36.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$2K
- Genentech USA, Inc.$1K
- Astellas Pharma US Inc$914
- AbbVie$826
- Novartis$466
- Apellis Pharmaceuticals, Inc.$425
- plus $1K from 16 others
What the payments were for
- Consulting fees$1502%
- Food & beverage$6,67197%
- Education$511%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 50 | $1,852 |
| Genentech USA, Inc. | 26 | $1,063 |
| Astellas Pharma US Inc | 28 | $914 |
| AbbVie(2 entities) | 32 | $826 |
| Novartis | 9 | $466 |
| Apellis Pharmaceuticals, Inc. | 16 | $425 |
| Coherus Oncology, Inc. | 3 | $179 |
| Harrow Eye, LLC | 2 | $154 |
| Cardinal Health 110 LLC | 1 | $150 |
| Regeneron | 1 | $113 |
| Kala Pharmaceuticals, Inc. | 1 | $110 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $100 |
| Alcon | 1 | $96 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $93 |
| Mallinckrodt Enterprises LLC | 3 | $71 |
| Dutch Ophthalmic, USA | 1 | $71 |
| Alimera Sciences, Inc. | 4 | $67 |
| Biogen | 2 | $45 |
| Bausch & Lomb Americas Inc. | 2 | $37 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Spark Therapeutics, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,891 in reported general payments places this provider in the 80th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 224 | $7,353 |
| Difluprednate | 25 | $3,314 |
| Ketorolac Tromethamine | 83 | $1,919 |
| MoxifloxacinMoxifloxacin Hcl | 58 | $1,032 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 49 | $711 |
| Latanoprost | 20 | $175 |
| Ofloxacin | 12 | $138 |
| Brimonidine Tartrate | 25 | $89 |
| Timolol Maleate | 16 | $84 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Orlando
- Matthew CunninghamOrlando$400K
- Sarina AminOrlando$138K
- Samuel Houston IiiOrlando$132K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.